MS
The startup develops a molecular diagnostics technology that analyzes tissue-specific cell-free circulating ribonucleic acid in blood samples to monitor organ damage. This early detection method provides physicians with critical genetic information to differentiate between healthy and disease states in patients.
Updated 18 months ago
Funding
$19.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
WSFunding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops a molecular diagnostics technology that analyzes tissue-specific cell-free circulating ribonucleic acid in blood samples to monitor organ damage. This early detection method provides physicians with critical genetic information to differentiate between healthy and disease states in patients.